Merck & Co Inc $56.74

down -1.34


31/7/2014 04:01 PM  |  NYSE : MRK  
Industries : Drugs / Drug Manufacturers - Major
Get Trend Analysis Icon Get MRK Trend Analysis - it has outperformed the S&P 500 by 4%

Partner Headlines

  1. 3 Reasons to Buy Merck for the Long Term

    Benzinga
  2. Len Schleifer's Science Focus Pays Off At Regeneron

    IBD
  3. Merck, J&J, Baxter Provide Healthy Dividend Stream

    IBD
  4. Amgen To Slash Workforce

    IBD
  5. Stocks Lower As Earnings Season Takes Back Seat To Geopolitical Uncertainties

    Benzinga
  6. Pharmaceutical ETFs Are Health Care Sector Standouts

    Benzinga
  7. Indices Remain Mixed; Merck Beats Expectations

    Benzinga
  8. Tuesday Morning Earnings Releases

    Benzinga
  9. Herbalife Falls On Downbeat Results; Windstream Shares Spike Higher

    Benzinga
  10. Merck, Pfizer Beat Q2 Earnings Estimates

    IBD
  11. Markets Open Higher; Merck Posts Upbeat Profit

    Benzinga
  12. Stocks Climb In Early Trade; Herbalife, El Pollo Loco Dive

    IBD
  13. Stock Futures Show Some Muscle; Merck, Cognex Rising

    IBD
  14. US Stock Futures Rise Ahead Of Earnings, Consumer Confidence Data

    Benzinga
  15. UPDATE: Merck Q2 Profit Beats Street View, Shares Rise

    Benzinga
  16. Earnings Scheduled For July 29, 2014

    Benzinga
  17. Stocks To Watch For July 29, 2014

    Benzinga
  18. Markets Little Changed Ahead Of The Federal Reserve's Policy Decision

    Benzinga
  19. Pfizer, Merck, Amgen Near Q2 Earnings Reports

    IBD
  20. Earnings Expectations For The Week Of July 28: Exxon, Pfizer, Twitter And ...

    Benzinga
  21. Benzinga Weekly Preview: FOMC In Focus, As Earnings Season Progresses

    Benzinga
  22. Week Ahead: July Jobs Report, FOMC and GDP

    FoxBusiness
  23. Facebook, Gilead Headline IBD 50's Top 5 Earnings

    IBD
  24. UnitedHealth Group Up on Weak Day for the Dow

    GuruFocus
  25. U.S. Markets Regain Losses from Last Week

    GuruFocus
  26. Abner Herrman Is Increasing Position in the Pharmaceutical Sector

    GuruFocus
  27. Senators Ask Gilead To Explain Sovaldi Pricing

    IBD
  28. Bristol-Myers Seeking Nivolumab Approval In Melanoma

    IBD
  29. Job or Invest: Growth Often Equals Happiness

    YCharts
  30. Markets Marginally Lower Ahead Of Earnings Season

    Benzinga
  31. Merck, Gilead Lead Race To Eradicate Hepatitis C

    IBD
  32. Exclusive: Enanta Pharmaceuticals CEO Jay Luly Discusses Hep C Pipeline

    Benzinga
  33. Markets Little Changed Ahead Of 4th Of July Break

    Benzinga
  34. Barclays Downgrades Pharmaceutical Sector

    Benzinga
  35. US Stock Futures Fall Ahead Of Home Sales Report

    Benzinga
  36. Exclusive: Hepatitis C Stock Valuation With Enanta CEO Jay Luly

    Benzinga
  37. Bristol-Myers Stock Up On Nivolumab Trial Success

    IBD
  38. Achillion

    IBD
  39. Dow, S&P 500 End At New Highs, Led By Auto Retailers

    IBD
  40. Achillion Could Win Idenix's Mystery Suitor: Analyst

    IBD
  41. Dow, S&P 500 Hit All-Time Highs As Volume Swells

    IBD
  42. 5-Star Biotech Stock Watch: Synta Pharmaceuticals

    Benzinga
  43. Stock Futures Hold Narrow Gains; Adobe Systems Up On Q2 Results

    IBD
  44. Allergan, Actavis Top Big Cap Pharmas Amid M&A Flurry

    IBD
  45. Achillion Gets Massive Price Target Hike On HCV Drugs

    IBD
  46. Achillion Gets Massive Price Target Hike On HCV Drugs

    IBD
  47. U.S. Equity Markets Continue to Hit New Highs

    GuruFocus
  48. UPDATE: Bank Of America Reiterates On Merck & Co. On Higher Sales Estimates

    Benzinga
  49. Feed Your Brain Daily: Read, Study, Mingle

    IBD
  50. Sovaldi and Drug Pricing: The United States of Saps

    YCharts
Trading Center